UBS Maintains a 'Buy' on Johnson & Johnson (JNJ); Management Meeting Reinforces Improving Outlook
Tweet Send to a FriendGet Alerts JNJ Hot Sheet
Price: $88.09 +0.73%
Rating Summary:
8 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
8 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade JNJ Now!
UBS maintains a 'Buy' on Johnson & Johnson (NYSE: JNJ) price target lowered from $72 to $69.
UBS analyst says, "We had an opportunity to meet w/ CFO Dominic Caruso & Vice Chairman Sheri McCoy. On our estimates, we bumped ’12 & ’13 EPS modestly by $0.02 to $5.19 (+4%) & $5.67 (+9%) as we now assume significant share repo to offset SYST issuance (Street: $5.24 & $5.63). Further, mgmt seemed more upbeat on ’12 margin expansion. We continue to model improving organic rev growth on Pharma new products & Consumer re-launches (~2.5% in ’11; ~4% in ’12; ~5.5% in ’13)."
"Returning to a margin expansion outlook - Pharma will be the strongest driver; launch expenses to persist but incremental spend will be less than sales growth. Consumer more or less as re-investment behind re-launched brands may be needed. Despite headwinds on price & volumes, MD&D will benefit from a major reorganization into 3 broad op groups while benefits from supply chain initiatives also play out. Including SYST, we model 60 / 110bps of op mgn expansion in ’12 / ’13 (40 / 70bps ex-SYST)."
For an analyst ratings summary and ratings history on Johnson & Johnson click here. For more ratings news on Johnson & Johnson click here.
Shares of Johnson & Johnson closed at $64.53 yesterday, with a 52 week range of $57.50-$68.05.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
UBS analyst says, "We had an opportunity to meet w/ CFO Dominic Caruso & Vice Chairman Sheri McCoy. On our estimates, we bumped ’12 & ’13 EPS modestly by $0.02 to $5.19 (+4%) & $5.67 (+9%) as we now assume significant share repo to offset SYST issuance (Street: $5.24 & $5.63). Further, mgmt seemed more upbeat on ’12 margin expansion. We continue to model improving organic rev growth on Pharma new products & Consumer re-launches (~2.5% in ’11; ~4% in ’12; ~5.5% in ’13)."
"Returning to a margin expansion outlook - Pharma will be the strongest driver; launch expenses to persist but incremental spend will be less than sales growth. Consumer more or less as re-investment behind re-launched brands may be needed. Despite headwinds on price & volumes, MD&D will benefit from a major reorganization into 3 broad op groups while benefits from supply chain initiatives also play out. Including SYST, we model 60 / 110bps of op mgn expansion in ’12 / ’13 (40 / 70bps ex-SYST)."
For an analyst ratings summary and ratings history on Johnson & Johnson click here. For more ratings news on Johnson & Johnson click here.
Shares of Johnson & Johnson closed at $64.53 yesterday, with a 52 week range of $57.50-$68.05.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Wells Fargo Upgrades Rosetta Resources (ROSE) to Outperform, Shares Attractive
- Deutsche Bank Downgrades TRW Automotive Holdings (TRW) to Hold
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
UBS
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
